Headache and temporal arteritis: When to suspect and how to manage

Current Pain and Headache Reports

Volumn 16, Issue 4, 2012, Pages 371-378

  Nahas, Stephanie J ^a  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

Diagnosis; Giant cell arteritis; Headache; Secondary headache; Temporal arteritis; Temporal artery biopsy; Treatment; Vasculitis

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHISTAMINIC AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; PROTON PUMP INHIBITOR;

ARTICLE; BLOOD VESSEL BIOPSY; CLINICAL FEATURE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DIAGNOSTIC IMAGING; DRUG MEGADOSE; ECHOGRAPHY; GASTRITIS; HEADACHE; HISTOPATHOLOGY; HUMAN; INCIDENCE; LABORATORY TEST; LOW DRUG DOSE; MAGNETIC RESONANCE ANGIOGRAPHY; MEDICAL HISTORY; NON INVASIVE MEASUREMENT; PATIENT MONITORING; PEPTIC ULCER; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; RACE DIFFERENCE; TEMPORAL ARTERITIS;

ADRENAL CORTEX HORMONES; BIOPSY; DIAGNOSIS, DIFFERENTIAL; FEMALE; GIANT CELL ARTERITIS; HEADACHE; HUMANS; INFLAMMATION MEDIATORS; MALE; NEUROLOGIC EXAMINATION; RISK ASSESSMENT; RISK FACTORS; TEMPORAL ARTERIES;

EID: 84865651193     PISSN: 15313433     EISSN: 15343081     Source Type: Journal    
DOI: 10.1007/s11916-012-0265-z     Document Type: Article

References (67)

1. Horton BT, Magath BT, Brown GE. Arteritis of the temporal vessels: Report of 7 cases. Proc Staff Meet Mayo Clin. 1937;12:548-53.
2. Gonzalez-Gay MA, Martinez-Dubois C, Agudo M, Pompei O, Blanco R, Llorca J. Giant cell arteritis: Epidemiology, diagnosis, and management. Curr Rheumatol Rep. 2010;12(6):436-42. This is a comprehensive review.
3. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders. Cephalalgia. 2004;24:9-160.
4. Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33(8):1122-8. (Pubitemid 20273297)
5. Dasgupta B, Borg FA, Hassan N, Alexander L, Barraclough K, Bourke B, et al. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology. 2010;49(8):1594-7.
6. Dodick DW. Pearls: Headache. Semin Neurol. 2010;30(1):74-81.
7. Kermani TA, Schäfer VS, Crowson CS, Hunder GG, Gabriel SE, Matteson EL, et al. Increase in age at onset of giant cell arteritis: A population-based study. Ann Rheum Dis. 2010;69(4):780-1. The Olmsted County data reflect an increased incidence in individuals over age 70 years.
8. Salvarani C, Crowson CS, O'Fallon WM, Hunder GG, Gabriel SE. Reappraisal of the epidemiology of giant cell arteritis in Olmsted County, Minnesota, over a fifty-year period. Arthritis Care Res. 2004;51(2):264-8. (Pubitemid 38468712)
9. Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, Miranda-Filloy JA, Gonzalez-Juanatey C, Martin J, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Care Res. 2009;61(10):1454-61. This is a review of geographic and phenomenological differences in epidemiology, including the influence of environmental and genetic factors.
10. Liozon E, Ouattara B, Rhaiem K, Ly K, Bezanahary H, Loustaud V, et al. Familial aggregation in giant cell arteritis and polymyalgia rheumatica: A comprehensive literature review including 4 new families. Clin Exp Rheumatol. 2009;27(1 Suppl 52):S89-94. The theory of a genetic predisposition to TA is defended in this article.
11. Ward TN, Levin M. Headache in giant cell arteritis and other arteritides. Neurol Sci. 2005;26 Suppl 2:S134-7. (Pubitemid 40796498)
12. Cullen JF, Coleiro JA. Ophthalmic complications of giant cell arteritis. Surv Ophthalmol. 1976;20(4):247-60.
13. Kale N, Eggenberger E. Diagnosis and management of giant cell arteritis: A review. Curr Opin Ophthalmol. 2010;21(6):417-22. This review focuses on clinical features and addresses novel treatment options.
14. Smetana GW, Shmerling RH. Does this patient have temporal arteritis? JAMA. 2002;287(1):92-101. (Pubitemid 34251681)
15. Villa-Forte A. Giant cell arteritis: Suspect it, treat it promptly. Cleve Clin J Med. 2011;78(4):265-70. This is a highly practical and useful review of the approach to patients with potential TA.
16. Gonzalez-Gay MA, Barros S, Lopez-Diaz MJ, Garcia-Porrua C, Sanchez-Andrade A, Llorca J. Giant cell arteritis: Disease patterns of clinical presentation in a series of 240 patients. Medicine. 2005;84(5):269-76. (Pubitemid 41368480)
17. Salvarani C, Cantini F, Macchioni P, Olivieri I, Niccoli L, Padula A, et al. Distal musculoskeletal manifestations in polymyalgia rheumatica: A prospective followup study. Arthritis Rheum. 1998;41(7):1221-6. (Pubitemid 28313424)
18. Lie JT. Aortic and extracranial large vessel giant cell arteritis: A review of 72 cases with histopathologic documentation. Semin Arthritis Rheum. 1995;24(6):422-31.
19. Evans JM, O'Fallon WM, Hunder GG. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann Intern Med. 1995;122(7):502-7.
20. Tatò F, Hoffmann U. Giant cell arteritis: A systemic vascular disease. Vasc Med. 2008;13(2):127-40. (Pubitemid 351954347)
21. Kermani TA, Warrington KJ. Recent advances in diagnostic strategies for giant cell arteritis. Curr Neurol Neurosci Rep. 2012;12:138-44. This excellent review summarizes diagnosis with particular attention to a critical analysis of imaging modalities in temporal arteritis.
22. Salvarani C, Cantini F, Boiardi L, Hunder GG. Laboratory investigations useful in giant cell arteritis and Takayasu's arteritis. Clin Exp Rheumatol. 2003;21(6 Suppl 32):S23-8. (Pubitemid 38016476)
23. Lopez-Diaz MJ, Llorca J, Gonzalez-Juanatey C, Peña-Sagredo JL, Martin J, Gonzalez-Gay MA. The erythrocyte sedimentation rate is associated with the development of visual complications in biopsyproven giant cell arteritis. Semin Arthritis Rheum. 2008;38 (2):116-23.
24. Parikh M, Miller NR, Lee AG, Savino PJ, Vacarezza MN, Cornblath W, et al. Prevalence of a normal C-reactive protein with an elevated erythrocyte sedimentation rate in biopsy-proven giant cell arteritis. Ophthalmology. 2006;113(10):1842-5. (Pubitemid 44442440)
25. Costello F, Zimmerman MB, Podhajsky PA, Hayreh SS. Role of thrombocytosis in diagnosis of giant cell arteritis and differentiation of arteritic from non-arteritic anterior ischemic optic neuropathy. Eur J Ophthalmol. 2004;14(3):245-57. (Pubitemid 38901797)
26. Walvick MD, Walvick MP. Giant cell arteritis: Laboratory predictors of a positive temporal artery biopsy. Ophthalmology. 2011;118 (6):1201-4.
27. Schmidt WA, Kraft HE, Vorpahl K, Völker L, Gromnica-Ihle EJ. Color duplex ultrasonography in the diagnosis of temporal arteritis. N Engl J Med. 1997;337(19):1336-42. (Pubitemid 27467767)
28. Karassa FB, Matsagas MI, Schmidt WA, Ioannidis JPA. Metaanalysis: Test performance of ultrasonography for giant-cell arteritis. Ann Intern Med. 2005;142(5):359-69. (Pubitemid 40293409)
29. Arida A, Kyprianou M, Kanakis M, Sfikakis PP. The diagnostic value of ultrasonography-derived edema of the temporal artery wall in giant cell arteritis: A second meta-analysis. BMC Musculoskelet Disord. 2010;11:44. This meta-analysis confirms the utility of the halo sign.
30. Karahaliou M, Vaiopoulos G, Papaspyrou S, Kanakis MA, Revenas K, Sfikakis PP. Colour duplex sonography of temporal arteries before decision for biopsy: A prospective study in 55 patients with suspected giant cell arteritis. Arthritis Res Ther. 2006;8(4):R116.
31. Geiger J, Bley T, Uhl M, Frydrychowicz A, Langer M, Markl M. Diagnostic value of T2-weighted imaging for the detection of superficial cranial artery inflammation in giant cell arteritis. J Magn Reson Imaging. 2010;31(2):470-4.
32. Both M, Ahmadi-Simab K, Reuter M, Dourvos O, Fritzer E, Ullrich S, et al. MRI and FDG-PET in the assessment of inflammatory aortic arch syndrome in complicated courses of giant cell arteritis. Ann Rheum Dis. 2008;67(7):1030-3. (Pubitemid 351956669)
33. Tso E, Flamm SD, White RD, Schvartzman PR, Mascha E, Hoffman GS. Takayasu arteritis: Utility and limitations of magnetic resonance imaging in diagnosis and treatment. Arthritis Rheum. 2002;46(6):1634-42. (Pubitemid 34620212)
34. Bley TA, Uhl M, Carew J, Markl M, Schmidt D, Peter H, et al. Diagnostic value of high-resolution MR imaging in giant cell arteritis. AJNR Am J Neuroradiol. 2007;28(9):1722-7. (Pubitemid 47598147)
35. Bley TA, Reinhard M, Hauenstein C, Markl M, Warnatz K, Hetzel A, et al. Comparison of duplex sonography and highresolution magnetic resonance imaging in the diagnosis of giant cell (temporal) arteritis. Arthritis Rheum. 2008;58(8):2574-8. This study promotes the notion that ultrasound and magnetic resonance imaging are comparable.
36. Lefebvre C, Rance A, Paul J, Beguin C, Bletry O, Amoura Z, et al. The role of B-mode ultrasonography and electron beam computed tomography in evaluation of Takayasu's arteritis: A study of 43 patients. Semin Arthritis Rheum. 2000;30(1):25-32. (Pubitemid 30644070)
37. Chung JW, Kim H, Choi YH, Kim SJ, Lee W, Park JH. Patterns of aortic involvement in Takayasu arteritis and its clinical implications: Evaluation with spiral computed tomography angiography. J Vasc Surg. 2007;45(5):906-14. (Pubitemid 46656326)
38. Brodmann M, Lipp RW, Passath A, Seinost G, Pabst E, Pilger E. The role of 2-18F-fluoro-2-deoxy-D-glucose positron emission tomography in the diagnosis of giant cell arteritis of the temporal arteries. Rheumatology. 2004;43(2):241-2. (Pubitemid 38219684)
39. Lehmann P, Buchtala S, Achajew N, Haerle P, Ehrenstein B, Lighvani H, et al. 18F-FDG PET as a diagnostic procedure in large vessel vasculitis-a controlled, blinded re-examination of routine PET scans. Clin Rheumatol. 2011;30(1):37-42.
40. Besson FL, Parienti J, Bienvenu B, Prior JO, Costo S, Bouvard G, et al. Diagnostic performance of 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: A systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2011;38(9):1764-72. Six controlled studies of PET in the evaluation of TA are analyzed in this article, with particular attention to diagnostic characteristics.
41. Henes JC, Müller M, Krieger J, Balletshofer B, Pfannenberg AC, Kanz L, et al. [18F] FDG-PET/CT as a new and sensitive imaging method for the diagnosis of large vessel vasculitis. Clin Exp Rheumatol. 2008;26(3 Suppl 49):S47-52.
42. Niederkohr RD, Levin LA. A Bayesian analysis of the true sensitivity of a temporal artery biopsy. Invest Ophthalmol Vis Sci. 2007;48(2):675-80. (Pubitemid 351260700)
43. • Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2009;68(3):318-23. This review details management strategies.
44. Marí B, Monteagudo M, Bustamante E, Pérez J, Casanovas A, Jordana R, et al. Analysis of temporal artery biopsies in an 18-year period at a community hospital. Eur J Intern Med. 2009;20 (5):533-6.
45. Breuer GS, Nesher G, Nesher R. Rate of discordant findings in bilateral temporal artery biopsy to diagnose giant cell arteritis. J Rheumatol. 2009;36(4):794-6.
46. Boyev LR, Miller NR, Green WR. Efficacy of unilateral versus bilateral temporal artery biopsies for the diagnosis of giant cell arteritis. Am J Ophthalmol. 1999;128(2):211-5. (Pubitemid 29379775)
47. Brack A, Martinez-Taboada V, Stanson A, Goronzy JJ, Weyand CM. Disease pattern in cranial and large-vessel giant cell arteritis. Arthritis Rheum. 1999;42(2):311-7. (Pubitemid 29072849)
48. Breuer GS, Nesher R, Nesher G. Effect of biopsy length on the rate of positive temporal artery biopsies. Clin Exp Rheumatol. 2009;27(1 Suppl 52):S10-3. This paper provides evidence that biopsies shorter than 5 mm are inadequate, and explains why biopsies of 20mm or longer are desirable.
49. Ray-Chaudhuri N, Ah Kiné D, Tijani SO, Parums DV, Cartlidge N, Strong NP, et al. Effect of prior steroid treatment on temporal artery biopsy findings in giant cell arteritis. Br J Ophthalmol. 2002;86(5):530-2. (Pubitemid 34454497)
50. Foroozan R, Deramo VA, Buono LM, Jayamanne DGR, Sergott RC, Danesh-Meyer H, et al. Recovery of visual function in patients with biopsy-proven giant cell arteritis. Ophthalmology. 2003;110 (3):539-42. (Pubitemid 36262736)
51. Neff AG, Greifenstein EM. Giant cell arteritis update. Semin Ophthalmol. 1999;14(2):109-12. (Pubitemid 29307704)
52. González-Gay MA, Blanco R, Rodríguez-Valverde V, Martínez-Taboada VM, Delgado-Rodriguez M, Figueroa M, et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: Predictors and response to treatment. Arthritis Rheum. 1998;41 (8):1497-504. (Pubitemid 28373132)
53. Chew SSL, Kerr NM, Danesh-Meyer HV. Giant cell arteritis. J Clin Neurosci. 2009;16(10):1263-8.
54. Mazlumzadeh M, Hunder GG, Easley KA, Calamia KT, Matteson EL, Griffing WL, et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: A double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum. 2006;54(10):3310-8. (Pubitemid 44622103)
55. Weyand CM, Kaiser M, Yang H, Younge B, Goronzy JJ. Therapeutic effects of acetylsalicylic acid in giant cell arteritis. Arthritis Rheum. 2002;46(2):457-66. (Pubitemid 34136584)
56. Nesher G, Berkun Y, Mates M, Baras M, Rubinow A, Sonnenblick M. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum. 2004;50(4):1332-7. (Pubitemid 38480844)
57. Lee MS, Smith SD, Galor A, Hoffman GS. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum. 2006;54(10):3306-9. (Pubitemid 44622102)
58. Narváez FJG, Bernad B, Gómez-Vaquero C, García-Gómez C, Roig-Vilaseca D, Juanola X, et al. Impact of antiplatelet therapy in the development of severe ischemic complications and in the outcome of patients with giant cell arteritis. Clin Exp Rheumatol. 2008;26(3 Suppl 49):S57-62.
59. Salvarani C, Della Bella C, Cimino L, Macchioni P, Formisano D, Bajocchi G. Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis. Rheumatology. 2009;48(3):250-3.
60. • Berger CT, Wolbers M, Meyer P, Daikeler T, Hess C. High incidence of severe ischaemic complications in patients with giant cell arteritis irrespective of platelet count and size, and platelet inhibition. Rheumatology. 2009;48(3):258-61. This article, along with references 55-59, underscores the importance of vigilance for vascular risk factors and the potential benefit of antiplatelet therapy.
61. Mahr AD, Jover JA, Spiera RF, Hernández-García C, Fernández-Gutiérrez B, LaValley MP, et al. Adjunctive methotrexate for treatment of giant cell arteritis: An individual patient data metaanalysis. Arthritis Rheum. 2007;56(8):2789-97. (Pubitemid 47237299)
62. Hoffman GS, Cid MC, Hellmann DB, Guillevin L, Stone JH, Schousboe J, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum. 2002;46(5):1309-18. (Pubitemid 34525840)
63. Spiera RF, Mitnick HJ, Kupersmith M, Richmond M, Spiera H, Peterson MGE, et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol. 2001;19 (5):495-501. (Pubitemid 32894598)
64. Jover JA, Hernández-García C, Morado IC, Vargas E, Bañares A, Fernández-Gutiérrez B. Combined treatment of giant-cell arteritis with methotrexate and prednisone: A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;134(2):106-14. (Pubitemid 32096337)
65. Hoffman GS, Cid MC, Rendt-Zagar KE, Merkel PA, Weyand CM, Stone JH, et al. Infliximab for maintenance of glucocorticosteroidinduced remission of giant cell arteritis: A randomized trial. Ann Intern Med. 2007;146(9):621-30. (Pubitemid 351650517)
66. Devauchelle-Pensec V, Jousse S, Destombe C, Saraux A. Epidemiology, imaging, and treatment of giant cell arteritis. Joint Bone Spine. 2008;75(3):267-72.
67. Martínez-Valle F, Solans-Laqué R, Bosch-Gil J, Vilardell-Tarrés M. Aortic involvement in giant cell arteritis. Autoimmun Rev. 2010;9(7):521-4. This article details that early recognition of aortic involvement in TA is paramount to avoid serious morbidity.